Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nepuvibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etesevimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ebronucimab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ormutivimab, an antibody targeting Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Frunevetmab, an antibody targeting NGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Relfovetmab, an antibody targeting NGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dovanvetmab, an antibody targeting IL31 (Feline).

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Riltovetbart, an antibody targeting IL31 (Canine).

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zamubafusp, an antibody targeting Human variable immunoglobulin light chain (N-terminal cryptic neo-epitope).

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zadoprubart, an antibody targeting BTLA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trevotamig, an antibody targeting EPCAM × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Remzistotug, an antibody targeting PVRIG.